focus -WSS

focus

author：focus 2025-09-27 12:47:32 - browse：24

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Welsh Carson private equity firm escapes from FTC antitrust case

WSS

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Russians and Belarusians back at Wimbledon as war in Ukraine continues

Can gargling with Listerine treat gonorrhea of the mouth?

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

AltruBio raises $225 million to develop ulcerative colitis drug

PBM executives asked to testify by House panel

focus

focus

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

10 states plan to sue EPA over standards for residential wood

Medical records are filled with copy

Churchill Downs extends trainer Bob Baffert's ban through 2024

Wildfire smoke exposes gaps in outdoor worker protections

EU climate chief is concerned over the expansion of the coal industry in China

The cancer drug shortage isn’t new — and neither are the solutions

AI for drug discovery: Experts on separating hype from reality

Drug repurposing or repositioning? The language matters

Class action alleges UnitedHealth concealed DOJ probe

hotspot

HHS's proposed rule does nothing to address the climate crisis

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

US judge blocks portions of new Florida elections law

Warren pushes Witty on UnitedHealth's control over physicians

AltruBio raises $225 million to develop ulcerative colitis drug

AltruBio raises $225 million to develop ulcerative colitis drug

leisure time

leisure time

knowledge

entertainment